Pfizer and Ranbaxy petition Supreme Court in Lipitor
Drugmakers accused of a pay-for-delay scheme have asked the US Supreme Court to review an appellate court’s decision that held plaintiffs do not need to calculate patent litigation costs to allege that a drugmaker cut an illegal deal with a generic competitor.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10